Anti-HBs antibody concentration ≥10 mIU/mL was considered seroprotective. Response to the additional dose of hepatitis A-containing vaccine was

defined as anti-HAV antibody concentration ≥15 mIU/mL in seronegative subjects, ≥4-fold increase in anti-HAV antibody concentration in subjects with pre-vaccination anti-HAV antibody concentrations <100 mIU/mL or check details ≥2-fold increase in anti-HAV antibody concentration in subjects with pre-vaccination anti-HAV antibody concentrations ≥100 mIU/mL. Response to the additional dose of hepatitis B-containing vaccine was defined as an anti-HBs antibody concentration ≥10 mIU/mL in seronegative subjects or a ≥4-fold increase in anti-HBs antibody concentration in seropositive subjects. The primary population for analysis was the according- to-protocol (ATP) cohort. Seroprotection/seropositivity rates, geometric mean concentration (GMC) of anti-HBs and anti-HAV antibodies, and vaccine response rates were calculated with 95% confidence intervals (95% CI). Two-sided standardized asymptotic 95% CI and Fisher exact p-values were calculated for the difference in seroprotection and response rates between groups (HAB group minus either the ENG + HAV or HBVX + VAQ group). Of the 596 subjects enrolled in the primary vaccination study (199 in the HAB group, 200 in the ENG + HAV group, and 197 in the HBVX + VAQ group),

506 returned at year 4 and received an additional dose of the same vaccine(s) used for priming (172, 170, and 164 in the three groups, respectively). Demographic characteristics of the Palbociclib ATP immunogenicity cohort at year 4 were similar between groups and were consistent with baseline characteristics in the primary Oxymatrine vaccination study. Mean (SD) age was 59.0 (9.38) years, 68.5% of subjects were overweight, 92.4% were taking concomitant medication, and 78.7% had a current medical condition.

Following primary vaccination (month 7), >97% of subjects were seropositive for anti-HAV antibodies. At year 4, the proportion of subjects remaining seropositive for anti-HAV antibodies was 97.3% in the HAB group, 93.9% in the ENG + HAV group, and 96.0% in the HBVX + VAQ group. Anti-HAV antibody GMCs were 212.9, 165.7, and 277.4 mIU/mL in the three groups, respectively, at this time. Anti-HBs seropositivity rates were 92.8% in the HAB group, 83.5% in the ENG + HAV group, and 77.8% in the HBVX + VAQ group at month 7 and 76.9, 61.9, and 51.6% in the three groups, respectively, at year 4. As shown in Figure 1A, respective percentages of subjects with antibody concentrations ≥10 mIU/mL were 91.7, 79.7, and 71.0% at month 7 and 57.1, 40.1, and 26.6% at year 4 (p≤ 0.005 for the HAB group vs the ENG + HAV group and p < 0.0001 for the HAB group vs the HBVX + VAQ group at both time-points).